Last updated: 2026-10-09 23:25:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Xenetic Biosciences, Inc. (XBIO) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $2.16, with a market capitalization of $5.18M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.87 to $10.24. This page covers its latest market performance, valuation, price trends and company information.
$5.18M | |
$2.12 | |
$1,074.00 | |
$1.87 | |
$2.12 | |
10.20K | |
88.91K | |
-- | |
$10.24 | |
$1.87 | |
-- | |
-- |
Xenetic Biosciences, Inc. (XBIO) is trading at $2.20 in after-hours trading as of 2026-10-09 20:04:00, up 3.54% ($0.07) from the regular-session close of $2.12.
After-hours trading shows how investors are pricing XBIO after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Xenetic Biosciences, Inc. (XBIO) moved from $2.32 to $2.16, representing a decline of 7.11% ($0.17).
The stock traded between $2.10 and $2.34 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 20.50 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 3.4%
XBIO is currently trading at $2.16, placing it 3.4% of the way from its 52-week low of $1.87 to its 52-week high of $10.24. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 2 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Xenetic Biosciences, Inc. (XBIO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.